MGA’s Christy Robinson Quoted in IAM Article on Patent Thickets
MGA’s Christy Robinson Quoted in IAM Article on Patent Thickets In Intellectual Asset Management (IAM), Fresenius Kabi Intellectual Property Chief Rachel Moodie discusses the worsening problem of patent thickets in the U.S. biosimilars market. From IAM:...
MGA Report Comes in at Number One at The Center for Biosimilars
MGA Report Comes in at Number One at The Center for Biosimilars The Center for Biosimilars has announced that MGA’s recent report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was the top-read article on its...
MGA Report Featured by The Center for Biosimilars
MGA Report Featured by The Center for Biosimilars On Thursday, The Center for Biosimilars, a sister site of The American Journal of Managed Care, published an article discussing the differences between the patent systems in the United States and Europe when it comes...
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing Alex Brill and Christy Robinson | Washington, DC The white paper offers policy options to improve access to affordable biosimilar medicines. WASHINGTON,...- Health Care Workforce Shortages: An Updated Look
- New MGA Analysis of the Adalimumab Biosimilars Market in the United States
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing the Recent Tax Policy Proposal
- Bipartisan Senate Bill Aims to Curb Drug Patent Abuse
- Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug
- New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
- New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit
- Narrow House GOP Victory Should Point Toward Policy Development Agenda
- Don’t Let Pandemic Fatigue Inhibit Pandemic Preparedness
- American Renewal: A Simpler, More Responsible, and Pro-Growth Tax System
